BIOSIMILARS NEDERLAND

Educational Meeting on Biosimilar Monoclonal Antibodies

Focus on implementation

Date: Thursday September 3, 2015; 10:00 - 17:00 h.
Location: VU University of Amsterdam, De Boelelaan 1105, Amsterdam

Program Symposium

Time schedule:

09:30 – 10:00	registration and reception
10:00 – 12:30	part I: technical aspects
12:30 – 13:30	lunch / networking
13:30 – 14:45	part II: Norway experience
14:45 – 15:00	tea break
15:00 – 17:00	part III: clinical and implementation aspects
17:00 – 18:00	drink & bite / networking

Chairpersons:
Coordinator: Prof.Dr. Arnold G. Vulto, Professor of Hospital Pharmacy, ErasmusMC Rotterdam
Morning co-chair: Dr. Anton Franken, Isala Zwolle and member Dutch MEB
Afternoon co-chair: Prof.Dr. Geert D'Haens, Professor in GE, AMC Amsterdam

Topics:

Biosimilars Demystified:
Paradigm shift in design, and licensing, but manufacturing and QC standards equal
Dr. Thijs Giezen, hospital pharmacist, AHZ Haarlem

The comparability exercise
Superiority physicochemical analysis Vs comparative clinical trials
Prof.Dr. Joao Goncalves, PharmD, Faculty of Pharmacy, Lisbon - Portugal

Extrapolation of Indications and Interchangeability, concerns and experiences
Dr. Hans Ebbers, pharmacist, Utrecht University

The Dutch Medicines Board Opinion on Biosimilars
Dr. Anton Franken, specialist internal medicine Isala Zwolle, and member of the Dutch Medicines Evaluation Board

Pharmacoeconomic potential of biosimilars
Prof. Dr. Marc Koopmanschap, Department of Health Policy and Management/iMTA, Erasmus University Rotterdam

Lunch Break / networking

The Norwegian model regarding expensive medicines and biosimilars:
Strategy towards the introduction of biosimilars in Norway: lessons learnt and results
Torfin Aanes, Head of Drug Procurement Cooperation LIS, Norway

How Norway handles the introduction of new expensive drug in the hospital
Asbjorn Mack, Health Economist LIS, Norway

Tea Break

Hurdles towards implementation of biosimilars
What uncertainties have prescribers towards biosimilars?
Prof.Dr. Ellen Moors, Department of Innovation Studies, Utrecht University

Clinicians' view on biosimilars: what learned clinical societies say.
Prof.Dr. Geert D'Haens, Professor of Gastroenterology, AMC Amsterdam

Patient perspective: why should I use biosimilars?
(to be confirmed)

Clinical research with biosimilars in The Netherlands
Dr. Lissy de Ridder, pediatric gastroenterologist, Sophia Children Hospital Rotterdam

Pharmacovigilance and monitoring requirements for the implementation of biosimilars in the hospital: Databases and patient-registries
Mathieu Tjoeng PharmD, hospital pharmacist and president Dutch Association of Hospital Pharmacists.

Panel discussion on unresolved issues and summary

Closure and drink & bite / networking

Sign up here

N.B.:
Accreditation requested at KNMP, NVZA and MDL, NIV, NVDV, NVK, NVR, NVRO, and NVU.

This symposium is organized by the Initiatiefgroep Biosimilars Netherlands
www.biosimilars-nederland.nl
info@biosimilars-nederland.nl